Company Filing History:
Years Active: 2006-2011
Title: Ingvil Sæterdal: Innovator in Cancer Immunotherapy
Introduction
Ingvil Sæterdal is a prominent inventor based in Oslo, Norway. He has made significant contributions to the field of cancer immunotherapy, focusing on the development of innovative peptides that can elicit immune responses against cancer cells. With a total of 3 patents, Sæterdal is recognized for his groundbreaking work in this critical area of medical research.
Latest Patents
Sæterdal's latest patents include a novel approach to cancer treatment through the use of isolated peptides. These peptides are fragments of protein products that arise from frameshift mutations in genes associated with cancer. The isolated peptides are capable of eliciting T cell immunity against cells harboring these mutations. Additionally, he has developed cancer vaccines and therapeutically effective compositions containing these peptides. Another significant invention relates to antigenic peptides derived from telomerase, which elicit T cell mediated immunity. This invention includes cancer vaccines and pharmaceutical compositions designed to generate T lymphocytes that can recognize and destroy tumor cells in mammals. More specifically, it provides a telomerase protein or peptide for use in methods of treatment or prophylaxis of cancer, focusing on generating a T cell response against telomerase.
Career Highlights
Ingvil Sæterdal is currently associated with Gemvax AS, where he continues to advance his research in cancer immunotherapy. His work has been instrumental in developing new therapeutic strategies that harness the body's immune system to fight cancer more effectively.
Collaborations
Sæterdal collaborates with notable colleagues, including Jon Amund Eriksen and Mona Møller, who contribute to the innovative research environment at Gemvax AS.
Conclusion
Ingvil Sæterdal's contributions to cancer immunotherapy through his patented innovations highlight the potential of peptide-based treatments in combating cancer. His ongoing research promises to pave the way for new therapeutic options in the fight against this devastating disease.